Following the publication of this article [1] concerns were raised about results presented in Figs 3-5, and 7. Specifically,
- The following panels appear to overlap:
- β-actin data in Fig 3A (T-47D cells), Fig 4A (lower panel), and Fig 4B (bottom panel)
- β-actin data in Fig 3B and Fig 4A (upper panel)
- β-actin data in Fig 3D and Fig 4B (middle panel)
- Fig 4A upper panel p53 and Fig 7A β-actin
- Fig 5A MCF-7 panels for Sam 68 (Cyto lanes) and β-actin (Mito lanes)
- The labelling for multiple panels in Figs 3 and 4 is incomplete, such that it is unclear which results were obtained from MCF7 cells and which results were obtained from T-47D cells.
The corresponding author stated that the original data underlying the published results are no longer available.
In light of the unresolved concerns, which call into question the reliability and integrity of the published results, the PLOS One Editors retract this article.
LH and BR did not agree with the retraction and stand by the article’s findings. CCW and KWC either did not respond directly or could not be reached.
Reference
Citation: The PLOS One Editors (2026) Retraction: Phospho-Aspirin-2 (MDC-22) Inhibits Estrogen Receptor Positive Breast Cancer Growth Both In Vitro and In Vivo by a Redox-Dependent Effect. PLoS One 21(1): e0341199. https://doi.org/10.1371/journal.pone.0341199
Published: January 16, 2026
Copyright: © 2026 The PLOS One Editors. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.